Karyopharm Therapeutics

Company snapshot

Karyopharm Therapeutics maintains 82 tracked programs across Myelofibrosis, Acute Myeloid Leukemia, Multiple Myeloma, Thymoma, Myeloma Multiple, Solid Tumors, Diffuse Large B-cell Lymphoma, Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL, Penta-refractory multiple myeloma and triple-class refractory multiple myeloma, Relapsed/Refractory Diffuse Large B-Cell Lymphoma

• 82 active pipeline program(s) linked via ClinicalTrials.gov.
• 38 US patent(s) indexed to this assignee profile.
• 82 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Karyopharm Therapeutics. Not investment advice.

• approval Jun 2, 2026

  Karyopharm's Selinexor Plus Ruxolitinib SENTRY Trial Data to be Presented at EHA 2026

• Peer + 0 momentum

  Teva Pharma

  TA overlap score 40

• Peer + 0 momentum

  AbbVie Deutschland GmbH

  TA overlap score 40

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 40

• Peer + 0 momentum

  Alaunos Therapeutics

  TA overlap score 26.8

• Peer + 0 momentum

  Cellectar Biosciences

  TA overlap score 23.4

• Peer + 0 momentum

  Prelude Therapeutics

  TA overlap score 22.6

• Peer + 0 momentum

  Cartesian Therapeutics

  TA overlap score 22.4

• Peer + 0 momentum

  C4 Therapeutics

  TA overlap score 20.8

Recent activity

Latest pipeline, patent, and corporate events for Karyopharm Therapeutics.

1. Jun 8, 2026 Clinical update

   XPORT-MF-034 — Phase 3

2. Jun 8, 2026 Clinical update

   XPORT-MM-028 — Phase 2

3. Jun 8, 2026 Clinical update

   XPORT-MF-044 — Phase 2

4. Jun 8, 2026 Clinical update

   XPORT-DLBCL-30 — Phase 3

5. Jun 8, 2026 Clinical update

   KCP-330-009 — Phase 2

View all clinical trial activity →

• What is Karyopharm Therapeutics?

  Karyopharm Therapeutics is a pharma organization headquartered in Newton, USA. Primary therapeutic focus areas include Myelofibrosis, Acute Myeloid Leukemia, Multiple Myeloma, Thymoma, Myeloma Multiple. NovaPharmaNews links 82 clinical program(s), 0 drug profile(s), and 38 patent

• Is Karyopharm Therapeutics publicly traded?

  Karyopharm Therapeutics appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Karyopharm Therapeutics develop or market?

  We link 53 drug profile(s) where Karyopharm Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/karyopharm-therapeutics#company-drugs.

• What are the latest developments for Karyopharm Therapeutics?

  In the last 12 months our linked public records show 82 trial program update(s) and 3 US patent grant(s) tied to this profile.

• What therapeutic areas does Karyopharm Therapeutics focus on?

  Karyopharm Therapeutics focuses on Myelofibrosis, Acute Myeloid Leukemia, Multiple Myeloma based on our analysis of their pipeline programs and drug development activities.